Results 191 to 200 of about 7,937 (220)

Transthyretin amyloid cardiomyopathy

Ugeskrift for Læger
Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark.
Sie Kronborg Fensman, Ali Hussein Jaber Mejren, Tor Skibsted Clemmensen, Steen Hvitfeldt Poulsen   +3 more
openaire   +2 more sources

Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy

American Journal of Cardiovascular Drugs, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by the aggregation and deposition of amyloidogenic misfolded transthyretin (TTR) in the myocardium. The gradual accumulation of insoluble TTR amyloid fibrils can result in restrictive cardiomyopathy and heart failure. Tafamidis (Vyndaqel®; Vyndamax®),
openaire   +2 more sources

Bio-Profiling of Transthyretin Amyloid Cardiomyopathy

JACC: Heart Failure, 2021
openaire   +2 more sources

Editorial Commentary: Advances in transthyretin amyloid cardiomyopathy

Trends in Cardiovascular Medicine, 2021
Merrill D, Benson, Noel R, Dasgupta
openaire   +2 more sources

Acoramidis: A New Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy

Annals of Pharmacotherapy
Objective: The objective of the study was to review acoramidis, a new transthyretin stabilizer, for treatment of transthyretin amyloid cardiomyopathy by means of pharmacology, efficacy, and safety. Data sources: An Embase, PubMed, and ClinicalTrials.gov search was conducted using ...
Taylor Clark, Rachel Lucas, Azadeh Nasuhidehnavi, Nathan Sauers, Kelly Bach   +4 more
openaire   +1 more source

Coexisting transthyretin and atrial natriuretic peptide amyloid on left atrium in transthyretin amyloid cardiomyopathy

Journal of Cardiology Cases
Atrial amyloidosis is primarily caused by atrial natriuretic peptide (ANP) amyloid deposition. The main precursor protein causing cardiac amyloidosis is transthyretin (TTR), also known as TTR amyloid cardiomyopathy (ATTR-CM). A 73-year-old man, who presented with external dyspnea, was diagnosed with decompensated heart failure due to atrial ...
Naoto, Kuyama, Seiji, Takashio, Kosuke, Nakamura, Kosaku, Nishigawa, Shinsuke, Hanatani, Hiroki, Usuku, Eiichiro, Yamamoto, Mitsuharu, Ueda, Toshihiro, Fukui, Kenichi, Tsujita   +9 more
openaire   +2 more sources

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Nature Reviews Drug Discovery, 2022
Eric Karran, Bart De Strooper
exaly  

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Chemical Reviews, 2021
Phuong H Nguyen, Ayyalusamy Ramamoorthy, Bikash Sahoo   +2 more
exaly  

Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

Signal Transduction and Targeted Therapy, 2023
Weihong Song
exaly  

Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes

Chemical Reviews, 2021
Danilo Milardi, Ehud Gazit, Sheena E Radford   +2 more
exaly